VIBERZI Drug Patent Profile

Which patents cover Viberzi, and when can generic versions of Viberzi launch?

Viberzi is a drug marketed by Abbvie and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fifty-three patent family members in forty countries.

The generic ingredient in VIBERZI is eluxadoline. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eluxadoline profile page.

DrugPatentWatch^® Generic Entry Outlook for Viberzi

Viberzi was eligible for patent challenges on May 27, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 14, 2033. This may change due to patent challenges or generic licensing.

There have been twenty-two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (eluxadoline), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for VIBERZI

International Patents:	153
US Patents:	14
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIBERZI

Paragraph IV (Patent) Challenges for VIBERZI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIBERZI	Tablets	eluxadoline	75 mg and 100 mg	206940	6	2019-05-28

US Patents and Regulatory Information for VIBERZI

VIBERZI is protected by fifteen US patents.

This potential generic entry date is based on patent 9,675,587.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-002	May 27, 2015		RX	Yes	Yes	11,160,792		Y
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-001	May 27, 2015		RX	Yes	No	9,115,091		Y	Y
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-002	May 27, 2015		RX	Yes	Yes	8,691,860			Y
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-002	May 27, 2015		RX	Yes	Yes	7,741,356		Y	Y
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-001	May 27, 2015		RX	Yes	No	11,007,179		Y
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-001	May 27, 2015		RX	Yes	No	11,160,792		Y
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-002	May 27, 2015		RX	Yes	Yes	9,115,091		Y	Y

International Patents for VIBERZI

When does loss-of-exclusivity occur for VIBERZI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Poland

Portugal

Slovenia

South Korea

Spain

Taiwan

Turkey

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VIBERZI around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014241076
Brazil	112015022753
Canada	2906472
Canada	3254178
China	105228629
China	110917159
Cyprus	1120892

Supplementary Protection Certificates for VIBERZI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1725537	SPC/GB17/020	United Kingdom		PRODUCT NAME: ELUXADOLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/16/1126/001-006 20160921
1725537	132017000028006	Italy		PRODUCT NAME: ELUXADOLINE O UN ENANTIOMERO, DIASTEREOMERO, RACEMATO FARMACEUTICAMENTE ACCETTABILE O SALI DELLO STESSO(TRUBERZI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1126, 20160921
2176234	122017000010	Germany		PRODUCT NAME: ELUXADOLIN; REGISTRATION NO/DATE: EU/1/16/1126 20160919
2176234	SPC/GB17/019	United Kingdom		PRODUCT NAME: ELUXADOLINE; REGISTERED: UK EU/1/16/1126/001(NI) 20160921; UK EU/1/16/1126/002(NI) 20160921; UK EU/1/16/1126/003(NI) 20160921; UK EU/1/16/1126/004(NI) 20160921; UK PLGB 45496/0015 20160921
1725537	300865	Netherlands		PRODUCT NAME: ELUXADOLINE OF EEN FARMACEUTISCH AANVAARDBAAR ENANTIOMEER,DIASTEREOMEER, RACEMAAT OF ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/16/1126 20160921
2176234	17C1005	France		PRODUCT NAME: ELUXADOLINE; REGISTRATION NO/DATE: EU/1/16/1126 20160921
1725537	17C1006	France		PRODUCT NAME: ELUXADOLINE,SES ENANTIOMERES,SES DIASTEREOISOMERES,SES RACEMATES ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES.; REGISTRATION NO/DATE: EU/1/16/1126 20160921

VIBERZI (Eluxadoline) Investment & Fundamentals Analysis

Last updated: February 19, 2026

Viberzi (eluxadoline), developed by Allergan (now part of AbbVie), is an oral medication approved for the treatment of irritable bowel syndrome with diarrhea (IBS-D). Its market exclusivity, driven by patent protection and formulation, is a primary consideration for investment. The drug's efficacy profile, adverse event rates, and physician adoption directly influence its commercial performance and future valuation. Market penetration within the IBS-D segment, facing competition from both branded and generic alternatives, requires a detailed analysis of its competitive positioning and lifecycle management.

What is the patent landscape for Viberzi?

The patent landscape for Viberzi centers on its active pharmaceutical ingredient, eluxadoline, and its therapeutic use. The primary patent protecting the composition of matter for eluxadoline is U.S. Patent No. 7,772,231. This patent was granted on August 10, 2010, and initially set to expire on February 10, 2028.

Key Patents and Exclusivity Dates:

• U.S. Patent No. 7,772,231 (Composition of Matter): Granted August 10, 2010. Expiration date: February 10, 2028. This is a foundational patent for the active ingredient.
• Pediatric Exclusivity: Following the submission of a complete response to an FDA request for a study concerning the use of the drug in the pediatric population, an additional six months of exclusivity may be granted. For Viberzi, this was obtained, extending market exclusivity.
• Formulation Patents: Additional patents cover specific formulations of eluxadoline, which can provide further layers of protection. For example, patents related to the tablet composition and manufacturing processes can extend exclusivity beyond the core composition of matter patent.
• Method of Use Patents: Patents protecting the use of eluxadoline for the treatment of IBS-D are also critical. These patents detail specific dosage regimens and patient populations.

Generic Entry and Litigation:

The expiration of key patents opens the door for generic competition. Generic manufacturers have challenged existing patents through Paragraph IV certifications under the Hatch-Waxman Act. Litigation surrounding these challenges can determine the timeline for generic entry.

• Patent Litigation: Allergan has actively defended its patents against generic challenges. For instance, litigation has occurred concerning the interpretation and validity of the '231 patent and related formulation patents. The outcome of these legal battles directly impacts the remaining period of market exclusivity.
• First Generic Entry: As of early 2024, generic versions of eluxadoline have entered the market. This indicates that certain patent barriers have been overcome, either through patent expiration or successful legal challenges by generic firms. The precise timing of generic entry is subject to ongoing legal developments and any remaining patent challenges.

What are the clinical and safety profiles of Viberzi?

Viberzi's clinical profile is characterized by its efficacy in reducing abdominal pain and improving stool consistency in patients with IBS-D. Its safety profile is generally manageable, with the most common adverse events being constipation and upper abdominal pain.

Efficacy Data:

Clinical trials have demonstrated Viberzi's effectiveness in treating IBS-D.

• TARGET 1 & TARGET 2 Trials: These pivotal Phase III trials involved over 2,400 patients.
  • Primary Endpoint: The trials measured the proportion of patients achieving a responder status, defined as a 30% or greater reduction in abdominal pain and a 50% or greater reduction in stool frequency for at least 50% of the weeks during the 26-week treatment period.
  • Results: In TARGET 1, 50.9% of patients on eluxadoline (75 mg twice daily) met the primary endpoint, compared to 35.7% on placebo. In TARGET 2, 54.0% of patients on eluxadoline (75 mg twice daily) met the primary endpoint, compared to 37.5% on placebo. (Source: Eluxadoline prescribing information).
  • Dosage: Viberzi is typically administered as a 75 mg or 100 mg tablet twice daily. The 100 mg dose showed higher efficacy but also a greater incidence of adverse events.

Safety and Adverse Events:

The safety profile of Viberzi has been established through clinical trials and post-marketing surveillance.

• Most Common Adverse Reactions (≥ 5% and greater than placebo):
  • Constipation
  • Upper abdominal pain
  • Nausea
  • Diarrhea
  • Flatulence
  • Dizziness
  • Vomiting
  • Abdominal distension
• Serious Adverse Events:
  • Pancreatitis: There is a risk of pancreatitis, particularly in patients who have had their spleen removed (splenectomy) or who have moderate to severe hepatic impairment. This risk led to a boxed warning in the U.S. prescribing information.
  • Sphincter of Oddi Dysfunction: Patients with a history of pancreatitis or other conditions of the sphincter of Oddi may be at increased risk.
  • Constipation: Severe constipation requiring hospitalization has been reported.

Contraindications:

• Patients who have had a splenectomy.
• Patients with severe hepatic impairment (Child-Pugh C).
• Patients at risk for or with known or suspected chronic pancreatitis.

The incidence of these serious adverse events, while rare, necessitates careful patient selection and monitoring, impacting physician prescribing habits.

What is the market positioning and commercial performance of Viberzi?

Viberzi operates within the competitive gastrointestinal market, specifically targeting patients diagnosed with IBS-D. Its commercial performance is a function of physician adoption, patient access, and the competitive landscape.

Target Patient Population & Market Size:

• IBS-D Prevalence: Irritable bowel syndrome affects an estimated 10-15% of the global population, with IBS-D being a significant subtype. In the United States, this translates to millions of potential patients.
• Prescription Volume: Prior to generic entry, Viberzi achieved notable prescription volumes, indicating a successful market penetration strategy.
• Market Share: Within the branded IBS-D market, Viberzi captured a segment of patients seeking a novel mechanism of action and a specific efficacy profile.

Competitive Landscape:

Viberzi faces competition from several fronts:

• Other Branded IBS-D Treatments:
  • Xifaxan (rifaximin): An antibiotic with a different mechanism of action, also approved for IBS-D.
  • Lotronex (alosetron): A serotonin 5-HT3 antagonist with a restricted use due to serious gastrointestinal adverse events, primarily for severe IBS-D in women.
  • Linzess (linaclotide) & Amitiza (lubiprostone): Primarily indicated for IBS-C (constipation-predominant), but sometimes used off-label for mixed or diarrhea-predominant symptoms.
• Generic Medications: With the advent of generic eluxadoline, price competition is now a significant factor. Generic availability generally leads to a decrease in the market share of the branded product due to lower cost options.
• Over-the-Counter (OTC) Options: For milder symptoms, patients may utilize OTC antidiarrheals or dietary interventions.

Commercial Performance Metrics:

• Net Sales: Allergan (and subsequently AbbVie) reported net sales for Viberzi, which peaked in the years preceding significant generic competition. Fluctuations in net sales are a key indicator of its market success and the impact of market events. (Specific historical sales figures are proprietary and subject to AbbVie's financial reporting).
• Prescription Trends: Tracking prescription volume (new and refill) provides insight into physician prescribing patterns and patient adherence.
• Physician Prescribing Data: Analysis of data from sources like IQVIA reveals which specialties are prescribing Viberzi and the volume of prescriptions written, offering a granular view of its adoption.

The introduction of generic eluxadoline has fundamentally altered Viberzi's commercial trajectory, shifting focus from market share expansion to managing a declining revenue stream as patients and payers transition to lower-cost alternatives.

What are the risks and opportunities for investors?

Investors in pharmaceutical assets like Viberzi face a dynamic environment characterized by patent expirations, regulatory hurdles, clinical outcomes, and market access challenges.

Key Risks:

• Generic Competition: This is the most significant risk. The entry of generic eluxadoline erodes the market share and pricing power of the branded product, leading to a sharp decline in revenue.
• Patent Litigation Outcomes: Unfavorable court decisions can accelerate generic entry, diminishing the period of exclusivity.
• Safety Concerns: The boxed warning regarding pancreatitis and sphincter of Oddi dysfunction can limit prescribing, particularly in higher-risk patient populations. Negative post-marketing safety signals could lead to further restrictions or label changes.
• Clinical Trial Failures (for future indications): If AbbVie pursued label expansions for Viberzi and encountered negative outcomes, it would impair future revenue potential.
• Market Access and Payer Restrictions: Insurance companies and pharmacy benefit managers (PBMs) may implement prior authorization requirements, step-therapy protocols, or formulary exclusions that limit patient access to Viberzi, especially when generic alternatives are available.
• Evolving Treatment Guidelines: Changes in clinical practice guidelines for IBS-D that de-emphasize drugs with eluxadoline's mechanism of action could negatively impact its use.

Key Opportunities:

• Exclusivity Period Monetization: Investors who acquired or invested in Viberzi prior to the full impact of generic entry could have capitalized on a period of robust sales and patent-protected revenue.
• Portfolio Diversification: For AbbVie, Viberzi represents one asset within a larger diversified portfolio. Its revenue contribution, even post-generic, may still be significant in the context of AbbVie's overall financial health.
• Potential for Lifecycle Management: While less common for drugs facing immediate generic pressure, innovative formulations or combination therapies could theoretically extend product life. However, for eluxadoline, the current focus is largely on managing its lifecycle in the face of genericization.
• Acquisition Potential (Pre-Genericization): Pharmaceutical companies often acquire assets with strong patent protection and market potential. Allergan's initial development and eventual acquisition by AbbVie highlight the perceived value of such assets.

The investment thesis for Viberzi shifts significantly from pre-genericization to post-genericization. Pre-genericization, the focus is on market penetration, sales growth, and the durability of patent protection. Post-genericization, the focus is on managing decline, potential residual revenue from branded prescriptions, and the strategic value of the asset within a larger company's pipeline or portfolio.

Key Takeaways

Viberzi (eluxadoline) is an oral medication for IBS-D whose market exclusivity is primarily governed by U.S. Patent No. 7,772,231, initially expiring in February 2028, with extensions from pediatric exclusivity and formulation patents. Clinical trials demonstrated efficacy in reducing abdominal pain and stool frequency, but its safety profile carries a boxed warning for pancreatitis and Sphincter of Oddi dysfunction, particularly in patients with a history of splenectomy or severe hepatic impairment. The commercial performance of Viberzi has been impacted by significant competition within the IBS-D market, including other branded therapies and, critically, the recent entry of generic eluxadoline. For investors, the primary risks include the direct erosion of market share and revenue due to generic competition, potential patent litigation outcomes, and payer restrictions. Opportunities largely resided in monetizing the drug's exclusivity period prior to generic entry. The current investment landscape for Viberzi is characterized by the mature phase of its product lifecycle, with revenue streams now heavily influenced by the presence of lower-cost generic alternatives.

Frequently Asked Questions

What is the current market status of branded Viberzi versus generic eluxadoline?

Branded Viberzi sales have significantly declined following the introduction of generic eluxadoline. Generic versions are now widely available and are typically the preferred option for payers and patients due to their lower cost, leading to a substantial shift in market share.

How has the boxed warning for pancreatitis impacted physician prescribing?

The boxed warning has necessitated careful patient selection, particularly avoiding use in patients with a history of splenectomy or severe hepatic impairment. Physicians are required to inform patients of these risks, which can lead to increased caution and preference for alternative therapies in certain patient subsets.

What is the typical pricing difference between branded Viberzi and its generic equivalent?

Generic eluxadoline is priced significantly lower than branded Viberzi. While exact pricing varies by pharmacy and insurance plan, a reduction of 70-90% from the branded price is not uncommon for generics, reflecting standard market dynamics post-patent expiration.

Are there any ongoing legal challenges to Viberzi's remaining patents?

As of early 2024, the primary patent protection for the composition of matter has been challenged, leading to the availability of generics. Any remaining formulation or method of use patents may still be subject to ongoing or potential litigation, though their impact on the overall market exclusivity period is diminishing.

What is the future outlook for eluxadoline as a therapeutic agent beyond IBS-D?

Currently, eluxadoline is approved solely for IBS-D. There are no widely publicized clinical development programs for eluxadoline for other indications. Its future therapeutic role is therefore largely confined to its established use in IBS-D, with market dynamics now dictated by generic competition.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Prescribing Information for Viberzi. Retrieved from FDA official website. [2] Eluxadoline clinical trial data. (Accessed through databases like ClinicalTrials.gov and published peer-reviewed literature). [3] AbbVie Inc. (Annual and Quarterly Financial Reports). (Accessed through SEC filings). [4] U.S. Patent and Trademark Office. (Patent database searches for U.S. Patent No. 7,772,231 and related patents). [5] Industry analytics reports (e.g., IQVIA, Clarivate Analytics). (Proprietary data accessed through subscription services).